semaglutide longevity news VisualAbstract: Once-weekly Reduces Body Weight in People with Obesity Weight-loss drugs 'slow down the

By Product Type, the semaglutide segment represented a significant share of about 35% in the Global GLP-1 Receptor Agonist Market in 2026

GLP-1 Patch is designed for convenient, mess-free daily use as part of your personal wellness routine

TRIUMPH-6 (weight maintenance): Active, but no longer recruiting (643 participants enrolled)

These agents have multiple effects relevant to brain health: improved glycemic control (lowering glucose spikes, avoiding hyperglycemia) weight loss, which reduces many risk factors (vascular disease, hypertension, dyslipidemia) possible reduction of systemic inflammation possible direct neural effects: crossingor affectingthe blood brain barrier

Conclusion: In our primary analysis, we did not observe a significantly different risk of MOF between treatment with GLP-1RA and DPP-4i

If you assume that only about half of that long-run demand response shows up in 2026, the lower U.S